Infrastructure
Milestone Alert: VRG Tx Launches Its In Vivo R&D Facility!

We are thrilled to announce the launch of our state-of-the-art animal in vivo facility, a crucial expansion to our existing in silico and in vitro capabilities.

This new addition enables VRG Tx to seamlessly integrate the full spectrum of drug discovery—from in silico de novo design, through in vitro optimization, to animal in vivo characterization.

With this new facility dedicated to animal studies, we're poised to accelerate our research and deliver solutions that meet real-world health challenges faster than ever.

Join us on this journey and be part of our success story!

Introduction
Link icon purple
WRITTEN BY
VRG Therapeutics
PUBLISHED ON
April 11, 2024
SHARE THIS ON
Linkedin purple icon share buttonFacebook purple icon share buttonX purple icon share button
WRITTEN BY
VRG Therapeutics
PUBLISHED ON
April 11, 2024
SHARE THIS ON
Linkedin purple icon share buttonFacebook purple icon share buttonX purple icon share button
Introduction
Link icon purple
Latest
News
The latest industry news, interviews, technologies, and resources.
View All News
Kv1.3
July 11, 2024
By VRG Therapeutics
New VRG Tx patent application filed!
White arrow icon up and right direction redirecting to Partner with US page
Team
June 11, 2024
By VRG Therapeutics
VRG Therapeutics among the top 30 startups to participate in the Labena Ventures Accelerator Program!
White arrow icon up and right direction redirecting to Partner with US page
Latest
News
The latest industry news, interviews, technologies, and resources.
Kv1.3
July 11, 2024
By VRG Therapeutics
New VRG Tx patent application filed!
White arrow icon up and right direction redirecting to Partner with US page
Team
June 11, 2024
By VRG Therapeutics
VRG Therapeutics among the top 30 startups to participate in the Labena Ventures Accelerator Program!
White arrow icon up and right direction redirecting to Partner with US page
View All News
Learn More
Million ways to improve life
Learn More
Million ways to improve life